BANK VONTOBEL AG | Market Closed - Bid/Ask 11:20:00 2024-06-25 am EDT | After market 11:15:00 am | |||
| 101 CHF | -.--% |
|
101.2 | +0.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|
Delayed Quote Swiss Exchange
Last update June 25, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Certificati Azionari e Obbl.ri |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| RMA0EV | |
| ISIN | CH1341853393 |
| Date issued | 2024-06-07 |
| Strike | 984 kr |
| Maturity | 2026-06-08 (707 Days) |
| Parity | 0.98 : 1 |
| Emission price | 100 CHF |
| Emission volume | N/A |
| Settlement | entrambi |
| Currency | CHF |
Technical Indicators
| Highest since issue | 101 CHF |
|---|---|
| Lowest since issue | 101 CHF |
| Spread | 8 CHF |
| Spread % | 0.79% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
950.4
DKK
Spread / Average Target
-5.49%
- Stock Market
- Certificates
- RMA0EV Certificat
